Skip to Main Content

Put aside for a moment the curiosity of why anyone would believe aspirin and fish oil might be an effective treatment for Duchenne muscular dystrophy, a rare, degenerative disease. There’s a more useful lesson from Monday evening’s Catabasis Pharma blowup: No amount of spinning bad data will turn a failed drug into an effective one.

Catabasis said its experimental drug, called edasalonexent, did not improve the muscle function of patients with Duchenne muscular dystrophy compared to a placebo. The outcome of the Phase 3 study is the end for the drug, and quite likely the entire company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.